Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO 10736945
APP PUB NO 20180369343A1
SERIAL NO

15856653

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides compositions and methods for treating a myopathy. In certain embodiments, the invention provides compositions and methods for treating, improving muscle function, and prolonging survival in a subject with X-linked myotubular myopathy (XLMTM). The present invention provides a method comprising systemic administration of a composition that induces the increased expression of myotubularin in the muscle of a subject. The invention provides sustained regional and global increases in muscle function.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • WAKE FOREST UNIVERSITY HEALTH SCIENCES; GENETHON; CHILDREN'S MEDICAL CENTER CORPORATION

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Beggs, Alan H Needham, US 8 32
Buj, Bello Ana Maria Paris, FR 13 62
Childers, Martin K Seattle, US 9 51

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Feb 11, 2028
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 11, 2032
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00